# Lawmakers Send Right to Try Medical Cannabis Act, Ibogaine Trials to Governor > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/right-to-try-medical-cannabis-act-ibogaine-trials-governor/ > **Published:** 2026-03-18T21:10:27-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:05:41-04:00 > **Clinical Summary:** Explore the Right to Try Medical Cannabis Act expanding patient access and ibogaine clinical trials in Mississippi, offering new treatment pathways. --- ✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearch[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)Neurology Why This Matters This legislation expands patients’ access to cannabis and ibogaine outside standard [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), which clinicians need to understand to counsel patients on efficacy, safety, and legal status of these treatments. Clinicians should recognize that Right to Try laws create a regulatory pathway distinct from FDA approval, requiring different informed consent discussions and monitoring approaches than conventional pharmaceuticals. Knowledge of these expanded access options helps clinicians respond appropriately when patients inquire about cannabis and ibogaine for conditions where standard treatments have failed. Clinical Summary Mississippi lawmakers have advanced legislation that would establish a Right to Try pathway for medical cannabis, allowing patients with serious or terminal conditions to access cannabis products outside standard regulatory approval processes. This measure, similar to Right to Try laws that exist for experimental pharmaceuticals, could provide patients with limited treatment options an additional avenue for [cannabis access](https://cedclinic.com/medical-cannabis-delivery-services-growth-dmv-jamaica/) while the state develops its formal medical cannabis program. The legislation reflects a growing policy trend of decoupling emergency access from conventional approval timelines, which may increase clinician involvement in informed consent discussions and treatment monitoring for patients pursuing this pathway. For physicians in Mississippi, this law could create both opportunities to discuss cannabis as a potential therapeutic option with appropriate patients and new documentation responsibilities regarding patient selection and outcomes tracking. Clinicians should familiarize themselves with the specific eligibility criteria and documentation requirements once the law is enacted to appropriately counsel patients on whether Right to Try cannabis access aligns with their clinical circumstances. Dr. Caplan’s Take “When we finally give patients legal access to cannabis through Right to Try provisions, we’re not just changing law—we’re removing a barrier that has forced desperate patients to choose between breaking the law or suffering without a treatment their physician might otherwise recommend, and that’s a clinical reality we should have addressed decades ago.” Clinical Perspective The Mississippi legislature’s passage of a Right to Try Medical Cannabis Act reflects growing momentum for compassionate access pathways, yet clinicians should recognize this occurs within a fragmented regulatory landscape where evidence quality remains uneven across cannabinoid formulations and indications. While right-to-try provisions can benefit patients with limited conventional options, the absence of standardized dosing protocols, robust safety monitoring, and peer-reviewed efficacy data for most cannabis products creates clinical uncertainty about appropriate patient selection and monitoring strategies. Healthcare providers in Mississippi and elsewhere will need to navigate the tension between patient autonomy and the evidentiary standards traditionally required for treatment recommendations, particularly given cannabis’s complex pharmacology and potential for drug interactions with common medications. The concurrent advancement of ibogaine trials signals broader openness to alternative therapeutics, but these parallel developments underscore the importance of maintaining critical appraisal skills when discussing emerging treatments with patients. Clinicians should stay informed about their state 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Lawmakers+send+Right+to+Try+Medical+Cannabis+Act%2C+Ibogaine+clinical+trials+to+governor+%40drcaplan&url=https%3A%2F%2Fmagnoliatribune.com%2F2026%2F03%2F18%2Flawmakers-send-right-to-try-medical-cannabis-act-ibogaine-clinical-trials-to-governor%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fmagnoliatribune.com%2F2026%2F03%2F18%2Flawmakers-send-right-to-try-medical-cannabis-act-ibogaine-clinical-trials-to-governor%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Lawmakers+send+Right+to+Try+Medical+Cannabis+Act%2C+Ibogaine+clinical+trials+to+governor+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fmagnoliatribune.com%2F2026%2F03%2F18%2Flawmakers-send-right-to-try-medical-cannabis-act-ibogaine-clinical-trials-to-governor%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://magnoliatribune.com/2026/03/18/lawmakers-send-right-to-try-medical-cannabis-act-ibogaine-clinical-trials-to-governor/](https://magnoliatribune.com/2026/03/18/lawmakers-send-right-to-try-medical-cannabis-act-ibogaine-clinical-trials-to-governor/) Further Reading Evidence Watch[The Brain Science Behind the Munchies – Nautilus Magazine](https://cedclinic.com/cannabis-appetite-stimulation-neuroscience/) Evidence WatchIGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial CED Clinic Blog[A single dose of cannabidiol increases ad libitum energy intake in healthy adults but does not affect postprandial glucose or lipid metabolism.](https://cedclinic.com/cannabidiol-effects-on-appetite/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [DOH sets conditions on proposed medical cannabis legalization](https://cedclinic.com/philippine-medical-cannabis-legalization-conditions/) Learn about the Department of Health's conditions on medical [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) and its impact on patient access and clinical care. [Read More](https://cedclinic.com/philippine-medical-cannabis-legalization-conditions/) [Executive order expands list of qualifying conditions for medical cannabis in Kentucky](https://cedclinic.com/executive-order-expands-list-of-qualifying-conditions-for-medical-cannabis-in-kentucky/) Discover how Kentucky's executive order broadens qualifying conditions, enhancing patient access to medical cannabis treatments. [Learn More](https://cedclinic.com/executive-order-expands-list-of-qualifying-conditions-for-medical-cannabis-in-kentucky/) [Medical Marijuana: Delivering Clinical Care in an Ever-Evolving Environment Event Details](https://cedclinic.com/medical-marijuana-delivering-clinical-care-in-an-ever-evolving-environment-event-details/) Explore clinical care strategies for [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) in a changing regulatory landscape, emphasizing patient safety and efficacy. [Explore Event](https://cedclinic.com/medical-marijuana-delivering-clinical-care-in-an-ever-evolving-environment-event-details/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).